Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Executive Summary

• Revive Therapeutics announced an update on its collaborative study with Defence R&D Canada – Suffield Research Centre evaluating Bucillamine as a potential treatment for nerve‑agent exposure.
• The study is slated to conclude with results in January 2026, and any findings will be released only with DRDC’s authorization.
• Revive reaffirmed its commitment to provide ongoing updates as the research progresses.

Key Details

• The Bucillamine study is being conducted jointly with DRDC, which supplies expertise, infrastructure, and scientific capabilities for medical‑countermeasure development.
• Recent discussions with DRDC indicate that the study’s final results are expected in January 2026.
• Publication of any data from the study will require explicit approval from DRDC.
• Revive will continue to issue updates on the status of the DRDC study as it moves toward completion.

Notable Quotes

(No direct quotes were provided in the release.)